Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000726126 | SCV000342156 | uncertain significance | not provided | 2016-06-30 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000726126 | SCV000573217 | uncertain significance | not provided | 2024-05-15 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function |
Ambry Genetics | RCV002314025 | SCV000849219 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2017-04-04 | criteria provided, single submitter | clinical testing | The p.E2051K variant (also known as c.6151G>A), located in coding exon 36 of the FLNA gene, results from a G to A substitution at nucleotide position 6151. The glutamic acid at codon 2051 is replaced by lysine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV000726126 | SCV001715434 | uncertain significance | not provided | 2020-01-15 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001855201 | SCV002315877 | benign | Heterotopia, periventricular, X-linked dominant; Melnick-Needles syndrome; Oto-palato-digital syndrome, type II; Frontometaphyseal dysplasia | 2025-01-08 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003323495 | SCV004029203 | uncertain significance | not specified | 2023-07-30 | criteria provided, single submitter | clinical testing |